The endogenous cardiac cannabinoid system: A new protective mechanism against myocardial ischemia

Archives des Maladies du Coeur et des Vaisseaux

Volumn 99, Issue 3, 2006, Pages 242-246

  Lamontagne, D ^a   Lepicier P ^a   Lagneux, C ^a   Bouchard, J F ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cannabinoids; Endothelium; Myocardial infarction; Nitric oxide; Type 2 cannabinoid receptors

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR CB1 AGONIST; CANNABINOID RECEPTOR CB2 AGONIST; ENDOCANNABINOID; MEMBRANE PHOSPHOLIPID; UNCLASSIFIED DRUG; CANNABINOID; CANNABINOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; NONHUMAN; RAT; ANIMAL; DRUG ANTAGONISM; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIAL ISCHEMIA; RECEPTORS, CANNABINOID;

EID: 33646181593     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
3. Munro S, Thomas KL, Abushaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
4. Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005;106:133-45.
5. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992,258:1946-9.
6. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998;38:179-200.
7. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synoptic signaling. Physiol Rev 2003;83:1017-66.
8. Hanus L, Abu-Lafi S, Fride E, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001;98:3662-5.
9. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002;301:1020-4.
10. Leggett JD, Aspley S, Beckett SRG, D'Antona AM, Kendall DA. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 2004;141:253-62.
11. Griffin G, Too Q, Abood ME. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 2000;292:886-94.
12. Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 1999;6:757-73.
13. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003;140:790-801.
14. van der Stelt M, Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004;271:1827-34.
15. Di Marzo V. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci 1999;65:645-55.
16. Piomelli D, Beltramo M, Glasnapp S, et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 1999;96:5802-7.
17. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993;46:791-6.
18. Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Agro AF. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem 1998;273:32332-9.
19. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 2001;276:35552-7.
20. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-80.
21. Hillard CJ, Auchampach JA. In vitro activation of brain protein kinase C by the cannabinoids. Biochim Biophys Acta 1994;1220:163-70.
22. Wartmann M, Campbell D, Subramanian A, Burstein SH, Davis RJ. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett 1995;359:133-6.
23. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61.
24. Bouchard JF, Lépicier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 2003;72:1859-70.
25. Lake KD, Compton DR, Varga K, Martin BR, Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1- like cannabinoid receptors. J Pharmacol Exp Ther 1997;281:1030-7.
26. Lake KD, Martin BR, Kunos G, Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 1997;29:1204-10.
27. White R, Hiley CR. The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br J Pharmacol 1998;125:533-41.
28. Wagner JA, Varga K, Jarai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999;33:429-34.
29. O'Sullivan SE, Kendall DA, Randall MD. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br J Pharmacol 2004;142:435-42.
30. Pacher P, Batkai S, Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol 2004;558:647-57.
31. Jarai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999;96:14136-41.
32. Chataigneau T, Feletou M, Thollon C, et al. Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br J Pharmacol 1998;123:908-74.
33. Plane F, Holland M, Waldron GJ, Garland CJ, Boyle JP. Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol 1997;121:1509-11.
34. Randall MD, Kendall DA. Endocannabinoids: a new class of vasoactive substances. Trends Pharmacol Sci 1998;19:55-8.
35. Randall MD, Alexander SP, Bennett T, et al. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 1996;229:114-20.
36. Randall MD, Kendall DA. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 1997;335:205-9.
37. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol 1998;274:H375-H381.
38. Varga K, Wagner JA, Bridgen DT, Kynos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998;12:1035-44.
39. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 1997;390:518-21.
40. Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 1998;76:824-36.
41. Wagner JA, Hu K, Bauersachs J, et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 2001;38:2048-54.
42. Batkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004;110:1996-2002.
43. Lagneux C, Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 2001;132:793-6.
44. Krylatov AV, Ugdyzhekoya DS, Bernatskaya NA, et al. Activa tion of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 2001;131:523-5.
45. Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 2002;55:619-25.
46. Lepicier P, Bouchard JF, Lagneux C, Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 2003;139:805-15.
47. Underdown NJ, Hiley CR, Ford WR. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 2005;146:809-16.
48. Di Filippo C, Rossi F, Rossi S, D'Amico M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol 2004;75:453-9.
49. Wagner JA, Hu K, Karcher J, et al. CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 2003;138:1251-8.
50. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005;434:782-6.
51. Lagneux C, Adam A, Lamontagne D. A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart. Int Immunopharmacol 2003;3:1511-8.
52. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 1997;334:R1-R2.
53. Lépicier P, Bibeau-Poirier A, Lagneux C, et al. Le monoxyde d'azote est un médiateur important de la protection du myocarde suite à l'activation du récepteur CB1 endothélial (abstract). Arch Mal Cœur 2005;98:377.